Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

SPATA22 Inhibitors

SPATA22 inhibitors constitute a class of chemical compounds designed to target and modulate the activity of the SPATA22 (Spermatogenesis-associated protein 22) gene. These inhibitors are primarily utilized in molecular and cellular research to gain insights into the biological functions and regulatory mechanisms of SPATA22 rather than for any direct applications. SPATA22 is a relatively less studied gene, and its precise role in cellular processes remains under investigation. Inhibitors targeting SPATA22 are employed as valuable tools to elucidate the functions of this gene and its involvement in various cellular pathways. The mechanism of action of SPATA22 inhibitors typically involves interfering with the expression or function of SPATA22 at the molecular level. These inhibitors can act through various modes, such as inhibiting transcription factors or epigenetic modifiers that regulate SPATA22 expression, disrupting protein-protein interactions involving SPATA22, or modulating post-translational modifications of SPATA22 protein itself. Researchers use these inhibitors to explore the consequences of altered SPATA22 activity on cellular processes, including spermatogenesis, cell cycle regulation, or any other biological functions associated with SPATA22. By perturbing SPATA22 function, scientists aim to unravel its molecular roles and the broader impact it may have on cellular physiology, without necessarily targeting it for purposes. Thus, SPATA22 inhibitors serve as indispensable tools for advancing our fundamental understanding of this gene and its significance in various biological contexts.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$226.00
$846.00
1
(0)

JQ1 is a BET bromodomain inhibitor that disrupts the interaction between BET proteins and acetylated histones, leading to the inhibition of gene transcription. This indirectly affects SPATA22 regulation.

I-BET 151 Hydrochloride

1300031-49-5 (non HCl Salt)sc-391115
10 mg
$450.00
2
(0)

I-BET151, like JQ1, is a BET bromodomain inhibitor that disrupts the interaction between BET proteins and acetylated histones, impacting SPATA22 expression through epigenetic regulation.

EPZ6438

1403254-99-8sc-507456
1 mg
$66.00
(0)

Tazemetostat is an EZH2 inhibitor that can potentially affect SPATA22 expression by modulating the epigenetic landscape via inhibition of EZH2.

SGC-CBP30

1613695-14-9sc-473871
sc-473871A
5 mg
10 mg
$178.00
$338.00
(0)

SGC-CBP30 is a CREB-binding protein (CBP) inhibitor that can impact SPATA22 expression through modulation of CBP's transcriptional co-activator function.

CPI-203

1446144-04-2sc-501599
1 mg
$170.00
(0)

CPI-203 inhibits the BET bromodomains, interfering with their role in transcription. This can indirectly affect SPATA22 expression by altering the epigenetic environment.

(S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4-hydroxyphenyl)acetamide

202590-98-5sc-501130
2.5 mg
$330.00
(0)

OTX015 is a BET bromodomain inhibitor, impacting SPATA22 expression through its influence on BET proteins and the associated transcriptional machinery.

GSK126

1346574-57-9sc-490133
sc-490133A
sc-490133B
1 mg
5 mg
10 mg
$90.00
$238.00
$300.00
(0)

GSK126 is a BET inhibitor that can disrupt the binding of BET proteins to acetylated histones, indirectly affecting SPATA22 transcription.